Susan Combs Scott, MD @SusanScottMD Twitter Profile

Susan Combs Scott, MD

@SusanScottMD

Thoracic Medical Oncologist at Johns Hopkins at Sibley @hopkinskimmel @sibleyonline

384Posts 850Followers 515Following

Similar User

@Joshua_Reuss

@JulieBrahmer

@JSabari

@dwightowenmd

@kamarroneMD

@drshieldsmd

@HopkinsThoracic

@DasMillie11

@LeXiuning

@chulkimMD

@MattGubensMD

@jennifermarksmd

@ipreeshagul

@ryangentzler

@MMarmarelis

Susan Combs Scott, MD Reposted

Susan Combs Scott, MD

@SusanScottMD

19 Oct

⁦@SusanScottMD⁩ discussing first line EGFR therapies #Flaura2 #MARIPOSA lots of evolving data #DCLung24 ⁦@StephenVLiu⁩

Susan Combs Scott, MD Reposted

First-line treatment for #EGFR NSCLC is more complex, with approvals for osimertinib (FLAURA), osi + chemo (FLAURA2), and amivantamab + lazertinib (MARIPOSA). Dr. @SusanScottMD at #DCLung24 highlights the space. Will we see a significant OS improvement?

Susan Combs Scott, MD Reposted

Susan Combs Scott, MD

@SusanScottMD

8 Sep

Congratulations to Dr. Julie Brahmer @JulieBrahmer - this year’s Paul A. Bunn Jr. Scientific Award winner for lifetime achievement and we’re ready to celebrate at #WCLC24!

Susan Combs Scott, MD Reposted

Susan Combs Scott, MD

@SusanScottMD

4 Sep

🚨Why should we study circulating tumor DNA (ctDNA)?🧬 Discover how my research on #ctDNA aims to uncover cancer drivers, enable earlier diagnosis, and pave the way for new treatments 💉💊 ⁦@MoffittNews⁩ ⁦@MoffittResearch⁩ #Womeninresearch #NSCLC #MoffittAmbassadors

Susan Combs Scott, MD Reposted

Susan Combs Scott, MD

@SusanScottMD

6 Sep

🌟 Unlock new possibilities in #LungCancer #Research Submit your abstract by Sept 30 ➡ce.ceconcepts.com/EGFR24 @jillfeldman4 @ZPiotrowskaMD @egfrresisters @StephenVLiu @HelenaYu923 @maryjofidlerMD @christine_lovly @CEC_onc #LCSM #EGFR #EGFRSummit

Susan Combs Scott, MD Reposted

Susan Combs Scott, MD

@SusanScottMD

9 Sep

Best block party and lots of dancing through the 70s, 80s, 90s and 2000s at the @IASLC 50th anniversary celebration! #WCLC24 @JulieBrahmer @FordePatrick @DrJNaidoo @SusanScottMD

Susan Combs Scott, MD Reposted

Susan Combs Scott, MD

@SusanScottMD

8 Sep

With the goal of addressing a key clinical question, which pts w lung cancer may benefit from adjuvant immunotherapy after neoadjuvant, today at #WCLC2024 we presented results of an exploratory individual pt level analysis of the #CM77T & #CM816 trials 1/

Susan Combs Scott, MD

@SusanScottMD

7 Jul

🚨 DC Cancer Community: Consider an exciting 🎥 event this week: A phycian-patient partnership became Mission-Driven Tech, a women’s health innovation powerhouse. @globalradonc @EveMcdavid I look forward to patient perspectives and expert discussion. eventbrite.com/e/mission-driv…

Mission-Driven Tech presents: An evening on equity and innovation

Source: https://t.co/3xziZUbbC6

Susan Combs Scott, MD Reposted

Susan Combs Scott, MD

@SusanScottMD

3 Jun

Very proud of the team! Helping define high risk EGFRm+ patients. #ASCO24 #LCSM

Susan Combs Scott, MD Reposted

Susan Combs Scott, MD

@SusanScottMD

15 May

CM77T @NEJM by Drs. Cascone @MARIANOPROVENCI Perioperative (chemo-nivo followed by adjuvant nivo) vs. neoadj chemo alone. Key image below, early days but new landmark analysis shows potential benefit from the adjuvant component for pts who have definitive surgery? #lcsm @IASLC

NEJM

@NEJM

15 May

In a randomized trial of perioperative nivolumab as compared with chemotherapy, 18-month event-free survival was 70% in the nivolumab group and 50% in the chemotherapy group at 2-year median follow-up. Read the full CheckMate 77T phase 3 trial results: nej.md/3VaMtbX

Susan Combs Scott, MD Reposted

Susan Combs Scott, MD

@SusanScottMD

16 May

With FLAURAishing new frontline combination therapies for EGFR+ mNSCLC yet incomplete data—What to do NOW in clinic? 🆘 @DrSteveMartin & I share our thoughts for #ASCODailyNews 👇🏽 dailynews.ascopubs.org/do/deciding-be… @ASCO @OncoAlert #lcsm

Susan Combs Scott, MD Reposted

Susan Combs Scott, MD

@SusanScottMD

16 May

Outcomes with first-line osimertinib in 37 pts with rare atypical #EGFR exon 19 or compound mutations in #JTOCRR @JTOonline from Dr. @SusanScottMD @tiacheunkarndee RR 76%, median PFS 13m, time to discontinuation 22m, mOS 36m. jtocrr.org/article/S2666-…

First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound...

Source: https://t.co/SCiW2dsRqc

Susan Combs Scott, MD Reposted

Susan Combs Scott, MD

@SusanScottMD

16 May

My colleague Dr. @michaelconroy from @HopkinsThoracic discussing #KN671 in addition to other neoadjuvant/perioperative studies at the #LungCancerSymposium with the #CancerSupportCommunity! #nsclc #lcsm @SusanScottMD @Joshua_Reuss

Susan Combs Scott, MD Reposted

Susan Combs Scott, MD

@SusanScottMD

2 May

If you’re in the DMV, Dr. @michaelconroy and I will be discussing updates in #NSCLC on May 16th at the #LungCancerSymposium. RSVP by May 9th: cancersupportcommunity.salsalabs.org/lung-cancer-sy… #LCSM @HopkinsThoracic @JohnsHopkins @MedStarGUH @GeorgetownHOF @LombardiCancer @Georgetown

Susan Combs Scott, MD Reposted

Susan Combs Scott, MD

@SusanScottMD

11 May

I am deeply grateful for the time and effort the Next Wave Investigators in Thoracic Oncology Faculty have invested in mentoring us this weekend! @BioAscend This is a PRIME opportunity for career development!! Thank you, co-chairs Drs. @JulieBrahmer & @RamalingamMD ⬇️

Susan Combs Scott, MD

@SusanScottMD

21 Apr

These wonderful people 🤠🫁🩺 #TexasLung24 @TLCconference @BrendonStilesMD @esinghimd @Latinamd @StephenVLiu @Joshua_Reuss @NarjustFlorezMD @JulieBrahmer @drshieldsmd @christine_lovly @jpmd901 @ChristianRolfo @tigirlily

Susan Combs Scott, MD

@SusanScottMD

21 Apr

The best of the best!

Dr. Estela Rodriguez

@Latinamd

21 Apr

Find yourself a mentor who dances with you and don’t let go. #SheforShe #WomeninThoracicOncology #lcsm #TexasLung24 @SusanScottMD @JulieBrahmer @KimmelCancerCtr @HemOncWomenDocs #mentoringmatters

Susan Combs Scott, MD Reposted

Susan Combs Scott, MD

@SusanScottMD

21 Apr

Find yourself a mentor who dances with you and don’t let go. #SheforShe #WomeninThoracicOncology #lcsm #TexasLung24 @SusanScottMD @JulieBrahmer @KimmelCancerCtr @HemOncWomenDocs #mentoringmatters

Susan Combs Scott, MD Reposted

Susan Combs Scott, MD

@SusanScottMD

20 Apr

What a fun meeting @TLCconference! Thank you @StephenVLiu and Tina Cascone for being amazing hosts and congrats 👏to our thoracic queens- @marinagarassino @HwakeleeMD for a fabulous debate! This is easy to judge/there is no debate-a perfect score of 10 for the best conference!

Susan Combs Scott, MD Reposted

Susan Combs Scott, MD

@SusanScottMD

11 Apr

Dr. @SusanScottMD at #PLCClive24 with an overview of #EGFR exon 20 mutant NSCLC, where amivantamab is our new first line standard (with chemotherapy) and #HER2 mutant NSCLC, where the HER2 ADC trastuzumab deruxtecan is the approved targeted option. @MedscapeLIVE